New cancer drug enters first human trials
Disease control
Ongoing
This is the first study in humans of a new immunotherapy drug called BPT567 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, check for side effects, and see how the body processes the drug. Research…
Phase: PHASE1 • Sponsor: Bright Peak Therapeutics Inc • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC